Nefrodialisis S.A.S. is a company of nephrologists founded in 1996 in Medellín, Colombia. It provides services to the Kidney Institute, in Medellín, attending peritoneal dialysis patients
​
From the academic point of view, Nephrodialysis remains in continuous activity. Residents from Colombia and other countries have been received and permanent updating meetings are held, through magazine clubs and topic discussions. To highlight, the symposium "Nephrology a Day in a Day" has been organized every year without interruption since 2008. Between 2020 and 2022, given the restrictions for massive group meetings due to Covid-19, they were held via webinar, with outstanding data on participation in the two years as a whole; 12,000 physicians registered and 3,600 attendees, including 800 internal medicine specialists, 550 nephrologists, 50 cardiologists, 60 resident physicians, several endocrinologists, and a large number of general practitioners and auditors, doctors in charge of cardiovascular and renal risk programs , diabetes and high blood pressure. There were attendees from all over Colombia and from 15 countries in America, Europe and Africa. These figures positions our event as outstanding in Nephrology in Colombia. This year the symposium will be presented, for the first time, both in person and via webinar.
​
For 2023, the XVI Symposium is scheduled to be held on saturdau, July 15, maintaining the philosophy of holding the event in one day, thus respecting the valuable time of each doctor and generating the opportunity of being up to date in a booming branch of medicine, such as Nephrology. The topics, will be varied, especially in the cardiometabolic area, arterial hypertension, type 2 diabetes, glomerular disease and chronic renal failure. In our website, www.nefrologiaaldiaenundia.com, you can find the audio and video recordings of the conferences given at the XV Symposium 2022 as well as from previous years. These can be consulted free of charge by anyone.
I want to thank doctor Juan Diego Montejo, nephrologist, leader in his field, for his commitment and innovative ideas. Likewise, I once again highlight the very valuable assistance of Paola Cardona and engineer Juan Carlos Cardona for an impeccable job. Finally, two thanks must be given: first, to all the companies in the pharmaceutical area that have believed in this symposium and in our group, because with their help they have allowed Nefrodialisis to reach many doctors with continuing education, and, second, to the Colombian Association of Nephrology and Arterial Hypertension for the support granted and that has allowed a significant number of associates to continue with this update in academic aspects.
Cordially,
Ivan Villegas
Director, Nefrodialisis S.A.S.
On behalf of the Organizing Committee